A high proportion of PDL1+ expression in tumours is usually considered to suggest high probability of patient responding to anti-PD1/anti-PDL1 treatment, and thus mechanisms that correlate negatively with tumour size and positively correlate with PDL1+ expression might be helpful to couple with such treatment to improve outcome. This evidence concerns the gene PDCD1 and neoplasm.